A phase III trial of dalfampridine, or 4-aminopyridine in an oral extended-release formulation, has found that the agent appears to improve walking ability in MS patients (Goodman et al. Ann Neurol 2010; 68: 494-502).
Latest News
Mirtazapine, paroxetine associated with greater risk of weight gain
March 9, 2011The first meta-analysis of the effect of antidepressants on body weight has found that mirtazapine, paroxetine and amitriptyline are associated with a greater risk of weight gain (Serretti & Mandelli. J Clin Psychiatry 2010; 71: 1259-1272). Fluoxetine and bupropion were associated with some weight loss.
Deep brain stimulation: consensus recommendations
March 9, 2011An international consortium has published its recommendations on issues relating to deep brain stimulation (DBS) in patients with Parkinson’s disease (Bronstein et al. Arch Neurol 2010; epublished October 11, 2010).
White matter hyperintensities predict cognitive decline
February 23, 2011White matter hyperintensities are a predictor of cognitive decline in relatively healthy older subjects, according to data from the Alzheimer Disease Neuroimaging Initiative (Carmichael et al. Arch Neurol 2010; 67: 1370-1378).